Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles (az-abenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of the steroid. Suitable pro-drug groups include amino acid groups, succinate groups, phosphate groups, or sulfamate groups. The prodrugs of the disclosed compounds allow for improved oral bioavailability of the compounds that are inhibitors of human CYP 17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds and the corresponding prodrugs are useful for the treatment of conditions such as human prostate cancer, breast cancer, and prostate hyperplasia.
1. A method of inducing cell cycle arrest in a cell, comprising administering to the cell an amount of Compound 5:
wherein the amount of Compound 5 is sufficient to induce cell cycle arrest.
2. The method of claim 1 , wherein the cell cycle arrest is evidenced by downregulation of Cyclin D1 protein expression, downregulation of cyclin E2 mRNA, induction of G1/G0 growth arrest, downregulation of genes involved in cell cycle progression, or any combination thereof.
3. The method of claim 2 , wherein the G1/G0 growth arrest is evidenced by FACS analysis of DNA content.
4. The method of claim 1 , wherein the cell is a prostate cell.
5. The method of claim 4 , wherein the prostate cell is a cultured cell.
6. The method of claim 5 , wherein the cultured cell is a PC3 cell.
7. The method of claim 1 , wherein the cell originates from a prostate hyperplasia, prostate cancer, breast cancer, or other urogenital cancer.
8. The method of claim 1 , wherein the amount of compound 5 sufficient to induce cell cycle arrest is 20 μM of compound 5.
9. The method of claim 1 , wherein the induction of cell cycle arrest is associated with an increase in intracellular calcium levels in the cell.
10. The method of claim 1 , wherein the compound is formulated as a pharmaceutical composition.
11. The method of claim 10 , wherein the pharmaceutical composition is formulated for oral administration.
12. The method of claim 11 , wherein the pharmaceutical composition is formulated as a capsule, sachet, or tablet.
13. The method of claim 1 , wherein the amount administered is about 1 mg to about 500 mg per day.
14. The method of claim 1 , comprising co-administering to the prostate cell an additional cancer therapy and/or drug.
15. The method of claim 14 , wherein the additional cancer therapy and/or drug comprises an anti-androgen, a CYP17 inhibitor, a drug that prevent adrenal glands from making androgens, and/or a leutenizing hormone-releasing hormone agonist.
16. The method of claim 15 , wherein the anti-androgen is flutamide or nilutamide.
17. The method of claim 15 , wherein the CYP17 inhibitor is abiraterone.
18. The method of claim 15 , wherein the leutenizing hormone-releasing hormone agonist is leuprolide, goserelin, or buserelin.
19. The method of claim 15 , wherein the drug that prevent adrenal glands from making androgens is ketoconazole or amino glutethimide.
20. The method of claim 1 , wherein the administering is performed ex vivo.